Helixmith has found serious flaws in pharmacokinetic data from the first Phase III trial with its lead product Engensis (VM202) and has delayed making conclusions based on what were the first top-line results from a US study.
During a review of the recently completed Phase III study of Engensis versus placebo in 500 patients with painful diabetic...